Pancreatic Cancer Clinical Trial
Official title:
The Use of Multifrequency Bioimpedance Assessments as an Estimate of Perioperative Total Body Volume and Postoperative Fluid Resuscitation
Being able to accurately monitor patient bodily fluid levels during and after surgery is very
important, as there are a number of complications that can arise if a patient's fluid levels
become unbalanced, such as swelling within or pressure on various bodily organ systems. There
are several different ways that physicians can monitor a patient's fluid balance during and
after surgery, such as measuring the amount of urine output or the use of central venous
catheters which measure the pressure in the veins entering the heart. Most of these
techniques are invasive since they require tubes to be inserted into the body. A potential
alternative would be to use a noninvasive technique such as electrical bioimpedance (BIA).
Bioimpedance assessments work by using small electrical currents that can accurately predict
both the water surrounding the outside of cells in the body, as well as the total amount of
water in the entire body. Electrical bioimpedance assessments have been used to estimate
patient swelling following surgery (edema), to measure the volume of blood the heart is
pumping out, as well as to calculate body fat percentages.
The goal of this study is to relate this technology to fluid shifts within the body that
occur as a result of surgery, in particular, major intra-abdominal surgeries. By using
bioimpedance during and after surgery, the investigators will compare the data collected with
that calculated by using traditional measures of body fluid status, such as urine output and
intraoperative blood loss. During the study, the bioimpedance monitors will not replace the
standard bodily fluid monitors and will not interfere with their readings. Additionally, the
electrical current produced by the bioimpedance monitors is too small for patients to feel
and will not interfere with medical devices such as pacemakers.
Being able to accurately monitor patient bodily fluid levels during and after surgery is very
important, as there are a number of complications that can arise if a patient's fluid levels
become unbalanced, such as swelling within or pressure on various bodily organ systems. There
are several different ways that physicians can monitor a patient's fluid balance during and
after surgery, such as measuring the amount of urine output or the use of central venous
catheters which measure the pressure in the veins entering the heart. Most of these
techniques are invasive since they require tubes to be inserted into the body. A potential
alternative would be to use a noninvasive technique such as electrical bioimpedance (BIA).
Bioimpedance assessments work by using small electrical currents that can accurately predict
both the water surrounding the outside of cells in the body, as well as the total amount of
water in the entire body. Electrical bioimpedance assessments have been used to estimate
patient swelling following surgery (edema), to measure the volume of blood the heart is
pumping out, as well as to calculate body fat percentages.
The goal of this study is to relate this technology to fluid shifts within the body that
occur as a result of surgery, in particular, major intra-abdominal surgeries. By using
bioimpedance during and after surgery, the investigators will compare the data collected with
that calculated by using traditional measures of body fluid status, such as urine output and
intraoperative blood loss. During the study, the bioimpedance monitors will not replace the
standard bodily fluid monitors and will not interfere with their readings. Additionally, the
electrical current produced by the bioimpedance monitors is too small for patients to feel
and will not interfere with medical devices such as pacemakers.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|